ARCHIVES

In Brief: Guide Is Late, So RFP Deadline Extended; Real Cancer Mortality Increase Was .7%

This article is from The Cancer Letter archive.

Vol. 03 No. 04 | January 28, 1977

Download PDF Visit The Full Archive

Related Articles

Guest Opinion: Long Island Study’s Value Now Rests In Its Repository

November 2, 2002

In Brief: FCRC Committee Loses Chance To influence RFP; Recompetition To Remain On Schedule

November 5, 1976

Adamson, Henney Chair Silicone Task Force

April 25, 1992

Friends Of Cancer Research Plan September Launch

August 9, 1996

Funding opportunities listed.

July 16, 2004

The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.

May 7, 2004